Novus Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>NT</div>
NVUS -- USA Stock  

USD 16.62  0.35  2.06%

The upcoming quarterly report is expected on the 11th of November 2020. The stock just had it stock split. Novus Therapeutics has reported 1 for 18 split on 5th of October 2020. Novus Therapeutics Total Assets Per Share are relatively stable at the moment as compared to the past year. Novus Therapeutics reported last year Total Assets Per Share of 13.60. As of 10/05/2020, Quick Ratio is likely to grow to 5.06, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (17.1 M). As many millenniums are trying to avoid healthcare space, it makes sense to sum up Novus Therapeutics a little further and try to understand its current market patterns. We will check if the company can maintain a respectable level of debt while minimizing operating losses.
Published over two weeks ago
View all stories for Novus Therapeutics | View All Stories
Thinking to sell Novus (NASDAQ:NVUS) based on its current debt commitments?
Novus Therapeutics currently holds 236 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest Novus Therapeutics is not taking enough advantage from borrowing. One of the ways to look at asset utilization of Novus is to check how much profit was generated for every dollar of assets it reports. Novus Therapeutics secures a negative usage of assets of -46.57 %, losing $0.47 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Novus Therapeutics shows how discouraging it operates for each dollar spent on its assets.
Novus Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Novus Therapeutics, including all of Novus Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Novus Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Novus Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Novus Total Liabilities

Novus Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Novus Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Novus Therapeutics balance sheet include debt obligations and money owed to different Novus Therapeutics vendors, workers, and loan providers. Below is the chart of Novus short long-term liabilities accounts currently reported on its balance sheet.
You can use Novus Therapeutics financial leverage analysis tool to get a better grip on understanding its financial position

How important is Novus Therapeutics's Liquidity

Novus Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Novus Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Novus Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Novus Therapeutics's total debt and its cash.

Another Deeper Perspective

Net Loss for the year was (17.8 M) with profit before overhead, payroll, taxes, and interest of 0.

Asset Breakdown

Assets Non Current
Goodwill
10.2 M
Current Assets
Total Assets11.22 Million
Current Assets10.23 Million
Assets Non Current999,539
Goodwill1.67 Million

Novus Therapeutics latest fall is alarming

Novus Therapeutics latest coefficient of variation advances over 990.29. As of the 5th of October, Novus Therapeutics secures the Mean Deviation of 7.03, downside deviation of 5.09, and Risk Adjusted Performance of 0.1108. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novus Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Novus Therapeutics, which can be compared to its peers in the industry. Please verify Novus Therapeutics jensen alpha and semi variance to decide if Novus Therapeutics is priced some-what accurately, providing market reflects its recent price of 0.9 per share. Given that Novus Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Our Final Takeaway

While other entities in the biotechnology industry are either recovering or due for a correction, Novus Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 5th of October 2020, we believe Novus Therapeutics is currently undervalued. It barely shadows the market and projects quite high probability of distress in the next two years. Our primary 30 days Buy-Hold-Sell recommendation on the enterprise is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Novus Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com